Paf1C regulates RNA polymerase II progression by modulating elongation rate

Liming Hou\textsuperscript{a,b}, Yating Wang\textsuperscript{a,b}, Yu Liu\textsuperscript{c}, Nan Zhang\textsuperscript{a,b}, Ilya Shamovsky\textsuperscript{d}, Evgeny Nucler\textsuperscript{d,e}, Bin Tian\textsuperscript{c}, and Brian David Dynlacht\textsuperscript{c,f}

\textsuperscript{a}Department of Pathology, New York University School of Medicine, New York, NY 10016; \textsuperscript{b}Perlmutter Cancer Institute, New York University School of Medicine, New York, NY 10016; \textsuperscript{c}Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, NJ 07103; \textsuperscript{d}Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016; and \textsuperscript{f}Howard Hughes Medical Institute, New York University School of Medicine, New York, NY 10016

Edited by Robert Tjian, University of California, Berkeley, CA, and approved June 6, 2019 (received for review March 12, 2019)

Elongation factor Paf1C regulates several stages of the RNA polymerase II (Pol II) transcription cycle, although it is unclear how it modulates Pol II distribution and progression in mammalian cells. We found that conditional ablation of Paf1 resulted in the accumulation of unphosphorylated and Ser5 phosphorylated Pol II around promoter-proximal regions and within the first 20 to 30 kb of gene bodies, respectively. Paf1 ablation did not impact the recruitment of other key elongation factors, namely, Spt5, Spt6, and the FACT complex, suggesting that Paf1 function may be mechanistically distinguishable from each of these factors. Moreover, loss of Paf1 triggered an increase in TSS-proximal nucleosome occupancy, which could impose a considerable barrier to Pol II elongation past TSS-proximal regions. Remarkably, accumulation of Ser5P in the first 20 to 30 kb coincided with reductions in histone H2B ubiquitylation within this region. Furthermore, we show that nascent RNA species accumulate within this window, suggesting a mechanism whereby Paf1 loss leads to aberrant, prematurely terminated transcripts and diminution of full-length transcripts. Importantly, we found that loss of Paf1 results in Pol II elongation rate defects with significant rate compression. Our findings suggest that Paf1C is critical for modulating Pol II elongation rates by functioning beyond the pause-release step as an “accelerator” over specific early gene body regions.

Paf1 complex | transcription elongation rate | RNA polymerase II | nucleosome occupancy

Recent studies have begun to focus on the rate-limiting steps that control transcriptional elongation in mammalian cells. Indeed, it is now recognized that many mammalian genes exhibit transcriptional pausing of RNA Polymerase II (Pol II) within the first 25 to 50 bp downstream of the transcription start site (TSS), demonstrated by the presence of promoter-proximal peaks of Pol II. It is also clear that the multistep regulation of elongation is critical for maintaining steady-state as well as inducible levels of gene expression (1, 2). Pausing is enforced by several multi-subunit complexes, including DRB sensitivity-inducing factor (DSIF, comprised of Spt4 and Spt5) and negative elongation factor (NELF). Phosphorylation of Ser2 of Pol II, DSIF, and NELF by positive transcription elongation factor b (pTEFb) results in dissociation of NELF, which coincides with pause release and entry of Pol II into the productive elongation phase (1).

Another factor with an established role in elongation is the Paf1 complex (Paf1C). Mammalian Paf1C consists of 5 subunits (Cdc73, Ctr9,Leod1, Pafl, and Skil8) which, together with Rtf1, assembles a multifunctional platform on gene regions (3, 4). The distribution of all subunits of yeast and mammalian Paf1C on chromatin has been mapped genome-wide (5–7). Paf1C is enriched on active genes. Intriguingly, the genomic profiles for Paf1C occupancy differs in yeast and mammalian cells: whereas yeast Pafl peaks over gene bodies and tapers off toward the TSS and transcription end site (TES), mammalian Paf1C occupancy is highest at both the TSS and TES, and in many cases, binding extends upstream of the TSS and well beyond the TES (6, 7).

Recent elegant cryo-EM studies from the Cramer laboratory have shown how mammalian Paf1C, Spt5/DSIF, and another elongation factor, Spt6, can interact with Pol II to assemble an activated elongation complex (8, 9). These structural studies suggested that Paf1C could displace NELF for pause release subsequent to phosphorylation of the latter protein by pTEFb (comprised of cyclin T/CDK9), and Spt6 might promote active Pol II elongation by opening the RNA clamp formed by DSIF. However, Spt5, Paf1C, and Spt6 associate with distinct regions of Pol II, and since neither Paf1C nor Spt6 makes contacts with the active site of Pol II, the stimulatory effect of both factors is likely to be allosteric in nature (8, 9). Despite these important conceptual advances, much remains unknown about whether or not the activities of Paf1C are mechanistically coupled with Spt5 and Spt6 and how they function during the early stages of transcription elongation. Moreover, much of our knowledge regarding these elongation factors has been obtained using yeast, and given differences between yeast and mammalian Paf1C—especially very large differences in gene lengths, which could influence elongation rates—additional analysis of the role of this elongation complex in mammalian cells is required.

Significance

The factors that regulate RNA polymerase II (Pol II) elongation rate and processivity are poorly understood. Here, we show that the Paf1 complex (Paf1C) modulates Pol II elongation rate, and loss of Paf1 results in accumulation of Ser5P in the first 20 to 30 kb of gene bodies, coinciding with reduction of histone H2B ubiquitylation specifically within this region. Moreover, reduced elongation rates provoked by Paf1 depletion resulted in defects in Pol II processivity and premature termination of transcription. Paf1 ablation did not impact the recruitment of other key elongation factors, suggesting that Paf1C function may be mechanistically distinguishable from each of these factors. Our data pinpoint Paf1C as a key modulator of Pol II elongation rates across mammalian genes.

Author contributions: L.H. and B.D.D. designed research; L.H., Y.W., and B.D.D. performed research; L.H., Y.W., Y.L., B.T., and B.D.D. contributed new reagents/analytic tools; L.H., Y.W., Y.L., N.Z., I.S., E.N., B.T., and B.D.D. analyzed data; and L.H., Y.W., and B.D.D. wrote the paper. The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: All large-scale data sets have been deposited in Gene Expression Omnibus (GEO) database, https://www.ncbi.nlm.nih.gov/geo (accession no. GSE116169).

\textsuperscript{1}To whom correspondence may be addressed. Email: brian.dynlacht@nyumc.org.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1904324116/-/DCSupplemental.

Published online June 28, 2019.
We have previously shown that depletion of Paf1C components leads to substantial defects in 3′ end processing and polyadenylation site (PAS) usage (7). We speculated that such processing defects could arise from Pol II stalling provoked by the loss of certain Paf1C subunits, such as Pafl, and indeed, multiple groups contemporaneously observed similar accumulations of Pol II over gene bodies upon Pafl removal (6, 7, 10). However, despite the biochemical and genetic studies in yeast that revealed a role for the PaflC as a positive regulator of elongation, the role of mammalian PaflC as an elongation factor remained unclear. Notably, one group suggested a role for this factor in enforcement of Pol II pausing (10, 11), whereas another study suggested that PaflC could, conversely, act by promoting pause release (6). The latter study attempted to link an increase in total and Ser5P Pol II to reduced enrichment of Cdk9 and Cdk12, but loss of Cdk9 or Cdk12 alone did not affect Pol II distribution or occupancy in their system (6). Moreover, the loss of Cdk9 resulted in a reduction of Pafl recruitment, prompting a model wherein the recruitment of Pafl is pTEFB dependent. Therefore, a mechanism that explains promoter-proximal Pol II pausing after loss of Pafl has remained elusive.

Here, we clarify these conflicting models by delineating the role of mammalian PaflC in transcriptional elongation and uncovering processes regulated by this complex. Using genome-wide sequencing of nascent RNA after conditional ablation of Pafl in murine myoblasts, we show that Pafl positively regulates elongation and Pol II progression, and in the absence of this protein, unphosphorylated Pol II accumulates around TSS-proximal pausing regions, an event that coincides with increased nucleosome occupancy in this region. Furthermore, the loss of Pafl triggers an accumulation of Ser5 phosphorylation (Ser5P) and overt reductions in H2B ubiquitylation (H2Bub) specifically over the first 20 to 30 kb of gene bodies. In addition, we found that loss of Pafl leads to severely reduced elongation rates and accumulation of nascent transcripts over early gene bodies. Since defects in elongation extend over gene bodies well beyond the TSS, our data suggest that Pafl regulates Pol II distribution beyond the promoter-proximal pause point. Our results thus support a model in which PaflC is an essential rate-limiting transcriptional elongation factor that functions within a defined window to promote Pol II processivity, elongation rates, transcription initiation, and progression past polyadenylation sites in early gene body regions to prevent accumulation of immature, truncated transcripts.

Results

Conditional Ablation of Pafl Results in Pol II Accumulation. In an effort to analyze the impact of complete loss of Pafl on Pol II distribution and transcriptional elongation, we used CRISPR/Cas9 to ablate the Pafl gene in the untransformed mouse muscle myoblast line, C2C12. We were unable to isolate stable populations of cells with homozygous Pafl deletions, suggesting that it is an essential gene. Therefore, we used gene editing to produce C2C12 cells with conditional expression of an sgRNA-resistant, doxycycline (Dox)-inducible Flag-Pafl transgene in a Pafl-deletion background, allowing us to study the reversibility of phenotypes associated with loss of this factor (Fig. 1A). We confirmed the editing of the Pafl gene through sequencing (SI Appendix, Fig. S1A). Pafl expression was reduced in these cells (termed Pafl-knockout [Pafl-KO]) by >90% within 1 d of Dox removal, and levels of exogenous Flag-Pafl were similar to endogenous Pafl after Dox induction (Fig. 1B). Consistent with its essentiality, we note that depletion of Pafl resulted in reduced cell growth rates after Dox removal for 2 d, although it did not affect cell viability after 4 d (SI Appendix, Fig. S1B). Therefore, we restricted our analyses to a window within 2 to 4 d after Dox removal. As an additional indicator of Pafl depletion, we showed that bulk H2B monoubiquitylation of lysine 120 (H2Bub) was decreased in whole cell extracts of 2 inducible Pafl-KO clones within 2 to 4 d after Dox removal, as expected from previous studies (Fig. 1B and SI Appendix, Fig. S1C) (7, 12). Importantly, H2Bub levels could be partially restored by Dox treatment of Pafl-depleted cells for 4 d, confirming that this Pafl null phenotype could be reversed and was not due to off-target or indirect effects (Fig. 1B).

We and others previously observed that Pol II accumulates on genes after silencing of mammalian Pafl (6, 7, 10). Pol II carboxyl-terminal domain (CTD) phosphorylation state is intimately linked to progression through the elongation cycle: unphosphorylated Pol II is first modified on Ser5 by cyclin A and then phosphorylated on Ser2 and Ser5 by cyclin-dependent kinase 9 (Cdk9) and Cdk12 (14). As an additional indicator of Pafl depletion, we showed that bulk H2B monoubiquitylation of lysine 120 (H2Bub) was decreased in whole cell extracts of 2 inducible Pafl-KO clones within 2 to 4 d after Dox removal, as expected from previous studies (Fig. 1B and SI Appendix, Fig. S1C) (7, 12). Importantly, H2Bub levels could be partially restored by Dox treatment of Pafl-depleted cells for 4 d, confirming that this Pafl null phenotype could be reversed and was not due to off-target or indirect effects (Fig. 1B).
H/CDK7 before recruitment of pTEFb (cyclin T/CDK9) and cyclin K/CDK12, which promote Ser2 phosphorylation, and Ser2-phosphorylated Pol II is associated with the active elongation complex. Using an antibody (SWG16) that primarily recognizes the unphosphorylated CTD of Pol II (13), we first examined Pol II occupancy before and after Paf1 removal by performing ChIP-seq and ChIP-qPCR in our inducible Paf1-KO cell line. We found that unphosphorylated Pol II levels were markedly increased on TSS-proximal regions after depletion of Paf1 on 5846 nonoverlapping, expressed genes (fragments per kilobase per million mapped reads [FPKM] > 1, RNA-seq) within 5 kb upstream of the TSS and 10 kb downstream of TSEs (Fig. 1C and D and SI Appendix, Fig. S1 D–F), consistent with previous experiments (7). Moreover, this phenotype could be partially rescued through expression of Paf1 (SI Appendix, Fig. S1E). We found that Paf1 depletion provoked Pol II accumulation irrespective of gene length or expression levels, and all genes exhibited a narrow band of accumulated polymerase near the TSS (Fig. 1D and SI Appendix, Fig. S1F). These results are consistent with recent findings in yeast that Paf1 regulates transcriptional elongation on nearly all genes (14). When we overlaid Paf1 recruitment with unphosphorylated Pol II in wild-type or Paf1-KO cells genome-wide, we found that Paf1 enrichment peaked slightly downstream (SI Appendix, Fig. S1G). Since Paf1 enrichment peaked downstream of unphosphorylated Pol II, we speculated that Paf1 could act to promote elongation at a point coinciding with, or subsequent to, Pol II CTD phosphorylation (see below).

We asked whether the impact of Paf1 ablation was restricted to this subunit or whether it could be generalized to other Pol1C components. We ablated 5 subunits using siRNAs (SI Appendix, Fig. S1H). We found that depletion of multiple subunits resulted in Pol II accumulation, although loss of Paf1 or Ctr9 had the greatest impact, and Leo1 or Ski8 depletion had minimal impact (SI Appendix, Fig. S1I). These results are interesting in light of recent cryo-EM studies that demonstrate mutually exclusive binding of Ctr9 and NELF to Pol II (8, 9). Furthermore, Ski8 is positioned on the elongation complex through binding of Ctr9 to Pol II, and based on its location within the complex, Leo1 could potentially play a role in stabilizing Spt5 and DNA rewinding upstream of Pol II and thereby facilitate elongation (8, 9). Our functional data, however, suggest that Ski8 and Leo1 may not play a prominent role in promoting Pol II progression.

Overall, our results confirm the utility of our Paf1-KO cells and suggest that depletion of multiple Pol1C subunits triggers genome-wide accumulation of unphosphorylated Pol II on TSS-proximal regions. These results suggested that Paf1 CTD triggers either increased initiation or defects in elongation rate, possibilities which we subsequently test below.

**Loss of Paf1 Triggers Genome-Wide Changes in Nucleosome Occupancy.** It is known that the TSS-proximal (+1) nucleosome is a major barrier to Pol II and that Pol II frequently pauses within a window encompassed by the first few downstream nucleosomes (15–18). Paf1C is thought to serve as a Pol II-associated platform that recruits factors required for Pol II progression, including the E3 ligase, RNF20, and other factors required for H2B ubiquitylation, a modification believed to enhance the rate of RNA Pol II progression (19, 20) and processivity (12). While the loss of Paf1 could explain the genome-wide reduction in RNF20 recruitment and erasure of H2Bub1, a mechanistic explanation for the observed increase in Pol II density was lacking. We therefore investigated potential changes in the chromatin landscape by comparing nucleosome locations and density in wild-type and Paf1-depleted myoblasts. First, using MNase-seq, we examined genome-wide nucleosome occupancy on all nonoverlapping expressed genes after Paf1 depletion in Paf1-KO cells. We found that Paf1-KO cells exhibited considerably enhanced nucleosome accumulation over TSS-proximal regions (Fig. 24 and SI Appendix, Fig. S2 A and B). We performed analogous studies on cells depleted of Paf1 through siRNA-mediated knockdown (KD) and observed similar results (SI Appendix, Fig. S2C), and importantly, we showed that increased nucleosome occupancy could be largely rescued by reexpression of Paf1, confirming that this defect was indeed specifically provoked by the loss of Paf1 (Fig. 24 and SI Appendix, Fig. S24). In parallel, we also performed assays for transposase-accessible chromatin (ATAC-seq) in siRNA-depleted (siPaf1) and control cells (siNS) (Fig. 2 B and C and SI Appendix, Fig. S2 D and E). These experiments confirmed the reduced accessibility of chromatin at TSS-proximal regions after Paf1 ablation. These findings suggested that Pol II accumulation could result from increased nucleosome occupancy around TSS-proximal regions, and loss of Paf1 could therefore impose a considerable barrier to Pol II progression.

**Loss of Paf1 Results in Accumulation of Ser5 Pol II in the First ~20 to 30 kb of Gene Bodies.** We sought to confirm and extend our understanding of aberrant Pol II accumulation in cells lacking Paf1. Our foregoing studies (detecting unphosphorylated Pol II) were unable to fully reveal the engaged polymerase molecules in elongation complexes. To that end, we performed ChIP-seq to detect Ser5 phosphorylation of the Pol II C-terminal domain (CTD), since promoter-paused Pol II exhibits Ser5 phosphorylation (21), and compared the genome-wide profiles in the presence and absence of Paf1. Heatmaps and metagene plots of Ser5-phosphorylated Pol II (Ser5 Pol II) within ±2 kb of the TSS indicated a significant increase in Ser5-phosphorylated Pol II (Ser5 Pol II) within ±2 kb of the TSS (Fig. 3 A and B). These experiments confirmed the reduced accessibility of chromatin at TSS-proximal regions after Paf1 ablation. These findings suggested that Pol II accumulation could result from increased nucleosome occupancy around TSS-proximal regions, and loss of Paf1 could therefore impose a considerable barrier to Pol II progression.

Hou et al. | PNAS | July 16, 2019 | vol. 116 | no. 29 | 14585

PNAS | July 16, 2019 | vol. 116 | no. 29 | 14585
Paf1 depletion (Fig. 3 B–D). The extent of Ser5 phosphorylation downstream of the TSS was independent of gene length (Fig. 3 B–D). On short genes, therefore, Pol II adopts a “persistently accumulated” state throughout the entire length of the gene, whereas on most long genes, the accumulated polymerase is restricted to a narrow, early gene body region downstream of the TSS (Fig. 3 B–D).

**Proteomic Analysis of Paf1C Interacting Proteins.** Next, we sought a mechanistic explanation for Pol II accumulation by analyzing the interactome of Paf1 using mass spectrometric (MS) sequencing. Previous studies that employed immunopurification of a Paf1C subunit (Cdc73) from human cancer cells led to the conclusion that this factor stably interacts with 3′ mRNA processing factors, specifically cleavage and polyadenylation factors, CPSF and CstF (22). On the other hand, parallel studies with antibodies directed against Paf1 and Leo1 did not precipitate these factors. In an effort to identify Paf1C-associated proteins in a nontransformed cell line, we isolated MNase-treated, soluble chromatin from our inducible KO expressing Flag-Paf1 or control non-Flag tagged wild-type C2C12 myoblast cell lines and performed Flag immunoaffinity purification and mass spectrometric sequencing (Materials and Methods). We identified a cadre of transcription and RNA processing and cleavage factors that were enriched in Flag-Paf1 expressing cells, with a >2-fold difference in the number of peptides recovered compared with control C2C12 myoblasts (Fig. 3 E and Dataset S1). Surprisingly, the cohort of polypeptides that we purified were largely nonoverlapping with those derived from cancer cells (22). In support of a positive role for Paf1 in elongation of Pol II, we found that all subunits of pTEFb (CDK9, Cyclin T1/T2) copurified, together with AFF4, a component of the Super Elongator Complex (SEC). We also identified the majority (12/14) of subunits associated with Integrator, a protein complex with roles in 3′ end processing of small nuclear (snRNA) and enhancer (eRNA) RNAs (23–26). Spt6 and an associated protein, IWS1, were also identified in our proteomic data, and other proteins with roles in elongation, including the Elongin complex (Elongin A and an Elongin A-binding protein, EboA-BP1/Rexo1) and TCERG1, copurified. Interestingly, we identified several transcript processing and termination factors, including CPSF3 and Pcf11, and Exosc10, an RNA exosome component responsible for degrading aberrant transcripts and RNA surveillance (27, 28). To confirm physiological interactions between Paf1 and a subset of these proteins, we induced expression of Flag-Paf1 in Paf1-KO cells, isolated chromatin, and performed immunoprecipitation and Western blotting. These studies confirmed the interaction of Paf1 with other known Paf1C subunits, Spt6, Elongin A, Pol II, and 2 subunits of the Integrator complex (SI Appendix, Fig. S3B). The complexes associated with Paf1 differ from those obtained through purification of Cdc73, suggesting that Paf1C could participate in subunit-specific or cell type-dependent interactions. These studies provide a resource for studying novel Paf1C activities in nontransformed cells and suggested that Paf1 indeed interacts with positive elongation factors to promote transcriptional elongation.

**Mechanistic Investigation of Factors that Coordinate Transcription Elongation.** We were intrigued by the relatively weak association of Paf1 with kinases that phosphorylate CTD Ser2 (CDK9) (SI Appendix, Fig. S3B and Dataset S1). Previous
studies indicated that the loss of Pafl could trigger increases in total and Ser5 phosphorylated Pol II and diminished recruitment of human CDK9 and CDK12 (6). Notably, genome-wide reductions in CDK9 recruitment after Pafl ablation were observed only after normalization to total Pol II (6). Our attempts at detecting CDK9 by ChIP were unsuccessful, however, perhaps owing to the availability of antibodies that did not effectively recognize the mouse protein bound to chromatin. Therefore, we interrogated Ser2 phosphorylation by ChIP-seq, as it reflects the activity of both kinases. We found that this modification was not reduced after Pafl depletion (SI Appendix, Fig. S3C). Rather, its occupancy increased, suggesting that the increase in accumulated Pol II was not due to depletion of CDK9 or CDK12 (also see below). Further, as before, the increase in Ser2 phosphorylation was independent of gene length and encompassed a region within ∼20 to 30 kb downstream of the TSS (SI Appendix, Fig. S3C).

Next, we examined 2 other elongation factors, Spt6 and FACT (Ssrp1 and Spt16), since we recovered peptides for each of these factors after Pafl purification, and they have been shown to modulate nucleosome occupancy to facilitate elongation. Spt6 is a histone H3 chaperone that enhances elongation, and FACT dissociates nucleosomal H2A/H2B dimers to promote Pol II progression. We were particularly interested in a potential role for Spt6, since yeast loss-of-function mutations result in defects in nucleosome occupancy (29, 30). Moreover, genetic and physical interactions between PaflC and Spt6, Spt5, and FACT have been observed in plants, yeast, and mammals (8, 9, 31–34), but the relationship between each of these proteins and PaflC has not been explored in the context of elongation in mammalian cells. PaflC can make direct contacts with Spt6 (9) and FACT, or it could interact through Pol II as an intermediary.

To determine whether these factors cooperate with PaflC to suppress Pol II accumulation, we first examined their protein levels after singly depleting each of these factors. We found that depletion of Pafl did not significantly impact the levels of Spt5, Spt6, or Spt16 or vice versa (SI Appendix, Fig. S4A). Next, we examined unphosphorylated Pol II levels after knockdown of Spt6 by ChIP-qPCR, and we found that loss of Spt6 also results in accumulation of unphosphorylated Pol II on the majority of loci we examined (SI Appendix, Fig. S4B). We therefore asked if the diminished nucleosome occupancy was due to the loss of Spt6 from chromatin. We examined the recruitment of Spt6 to several genes by ChIP-qPCR after depleting Pafl in Pafl-KO cells or using siRNAs. Surprisingly, we observed enhanced recruitment of Spt6 to cells depleted of Pafl through either approach (SI Appendix, Fig. S4 C and D). The impact of Pafl depletion could be attributed specifically to loss of this protein since Spt6 recruitment was rescued upon restoration of Pafl in KO cells (SI Appendix, Fig. S4C). To interrogate the genome-wide impact of Pafl removal, we performed ChIP-seq on Spt6 after depleting Pafl. We observed dramatically increased recruitment of Spt6 after loss of Pafl in both Pafl-KO (SI Appendix, Fig. S4 E–G) and Pafl KD cells (SI Appendix, Fig. S4 H–J). The accumulation of Spt6 was most obvious within early gene body regions (SI Appendix, Fig. S4 G and J). Moreover, we also observed enhanced recruitment of both FACT subunits (Spt6 and Ssrp1) after Pafl knockdown by ChIP-qPCR (SI Appendix, Fig. S5 A and B). Likewise, Spt6 was not globally depleted from chromatin after removal of Pafl, and instead, we observed dramatic increases in the occupancy of this factor by ChIP-seq (SI Appendix, Fig. S5 C–E).

Finally, we examined the interplay between Pafl and Spt5, a component of DSIF required for efficient transcriptional elongation in yeast and mammalian cells (8, 35–37), although we did not detect a stable association between Pafl and Spt5 in our proteomic experiments. We found that depletion of Pafl resulted in increased occupancy of Spt5 by ChIP-qPCR, and Spt5 occupancy reverted to wild-type levels upon reexpression of Pafl (SI Appendix, Fig. S5F). Interestingly, we showed that Spt5 accumulated genome-wide using ChIP-seq, and once again, Spt5 was most highly enriched within early gene bodies after loss of Pafl (SI Appendix, Fig. S5 G–I). When we normalized Sp16, Sp16, and Spt5 ChIP-seq data to Ser2-phosphorylated Pol II, however, the differences between wild-type and Pafl-depleted cells were largely negated, suggesting that these factors continued to travel with elongating Pol II (SI Appendix, Fig. S5I). These experiments therefore definitively rule out a role for loss of any of these elongation factors as an explanation for Pol II accumulation.

We conclude that the phenotypes associated with loss of PaflC—accumulation of Pol II and increased nucleosome occupancy (and loss of H2Bub and reduced elongation rates; see later)—cannot be ascribed to an inability to recruit key elongation factors, FACT, Spt5, or Spt6 to chromatin. These findings are important in light of the observed, extensive interactions that PaflC subunits make with both Spt6 and Spt5 (8, 9) and suggest that stable interactions of the latter factors with Pol II occur independently of Pafl.

The Impact of Pafl Loss on H2B Ubiquitylation. H2B monoubiquitylation has been shown to positively correlate with RNA Pol II elongation rates in mammalian cells (20). Moreover, H2Bub levels are tied to recruitment of Rado/RNRF20, which is further linked to PaflC and Pol II occupancy (19, 38–41). We initially investigated this modification in Pafl-KO cells using ChIP-qPCR. We found that H2Bub levels were decreased on a few expressed genes in wild-type myoblasts, and levels of this modification could be restored upon Pafl reexpression, attesting to the conclusion that ubiquitylation of this residue depends on the presence of Pafl (SI Appendix, Fig. S6A). We next performed ChIP-seq on H2Bub and observed reductions in H2Bub after Pafl removal (Fig. 4 A–E). This reduction occurred on all expressed genes, irrespective of gene expression levels and length (Fig. 4 A–E). We further validated these findings in siRNA-depleted (siPafl) cells (SI Appendix, Fig. S6 B–D).

Although the reductions in H2Bub could be anticipated based on the global loss of this modification in cell extracts (Fig. 1B), we found remarkable differences in the loss of this mark on 5′ versus 3′ ends of gene bodies. On long genes (>20 kb), Pafl was required for maximal ubiquitylation over the early gene body region, after which the modification was independent of this factor (Fig. 4 B, D, and E). For genes of intermediate length (10 kb to 20 kb) and short genes (<5 kb), we uncovered a strong dependence on Pafl throughout the entire gene body (Fig. 4 B, D, and E). Paradoxically, we note that Pafl is recruited throughout the gene bodies of long and short genes, and genome-wide profiles show increasing enrichment from 5′ to 3′ regions, with greatest enrichment at regions surrounding and downstream of the TES (Fig. 1D) and (7). However, metagene profiles of H2Bub ChIP-seq data show that the reductions in H2Bub occurred predominantly in a window ∼20 to 30 kb downstream of the TSS (Fig. 4F). Of note, we observed a strong correlation between enhanced Ser5P Pol II occupancy and reduced H2Bub over regions within 20 kb downstream of the TSS, in striking contrast with a window spanning +20 kb to the TES (Fig. 4G).

Since Pafl removal resulted in significant diminutions in H2Bub levels over early ∼20- to 30-kb gene body regions, we asked whether ablation of RNRF20, the E3 ligase responsible for ubiquitylation, could account for increased occupancy of unphosphorylated Pol II. Ablation of RNRF20 completely abolished cellular H2B ubiquitylation in whole cell extracts (SI Appendix, Fig. S6E), as expected. However, using ChIP-qPCR, we found no significant differences in unphosphorylated Pol II enrichment after RNRF20 silencing (SI Appendix, Fig. S6F). Importantly, these results suggest that Pol II accumulation after

Hou et al.
PNAS | July 16, 2019 | vol. 116 | no. 29 | 14587
Paf1 removal cannot be explained solely by the loss of RNF20, which probably results in a reduction of H2Bub throughout all genic regions rather than a reduction in a specific early gene body region, as we observed after Paf1 removal. Our results are notable because they suggest that (i) Paf1C plays a profound role in regulating H2B ubiquitylation over a specialized early gene body region, and Pol II progression is also intimately linked to Paf1C recruitment within this region; (ii) deposition and/or maintenance H2Bub levels becomes independent of Paf1C recruitment downstream of this window; and (iii) despite its demonstrated role in Pol II elongation, regulation of H2Bub levels via RNF20 cannot fully account for the role of Paf1 in promoting Pol II elongation.

Depletion of Paf1 Leads to Reduced Pol II Processivity. The above observations (increased nucleosome occupancy, Pol II accumulation, and reduced H2Bub levels) suggested that Paf1 loss could trigger significant changes in gene expression. Therefore, we examined steady-state gene expression levels after depleting Paf1 using RNA-seq. As shown in SI Appendix, Fig. S7A, 450 genes were up-regulated, and 447 genes were down-regulated in the absence of Paf1 (adjusted P value <0.05; log2 FPKM fold change >1) using DEseq2 analysis. Data from replicate experiments were highly concordant (SI Appendix, Fig. S7B). When we plotted heatmaps based on either Paf1 occupancy or gene length for these RNA-seq data, we found that there was a significant reduction in RNA-seq reads near the TSS in the sense direction, followed by increased read density in early gene body regions (SI Appendix, Fig. S7C–E). Moreover, we observed a noticeable global reduction in RNA-seq reads in downstream genic body regions (SI Appendix, Fig. S7D and E) (note the red signal in the last 2 panels in SI Appendix, Fig. S7D), which suggests that loss of Paf1 could result in a reduction of full-length transcripts. The increased RNA-seq reads in early gene body regions implies a defect in Pol II processivity (nucleotide additions per initiation event), accompanied by an increase in prematurely terminated shortened transcripts, as shown for individual genes (SI Appendix, Fig. S7F).

The observed increase in reads within early gene body regions, combined with decreased read counts further downstream, suggested that DEseq2 (which takes into account the entire gene

Fig. 4. Paf1-depleted cells exhibit reductions in H2Bub deposition over early gene body regions. (A) Heatmaps showing log2 ratio of H2Bub ChIP-seq densities at promoter-proximal regions (TSS −2 kb to TSS +2 kb) in Paf1-KO cells ranked according to decreasing Paf1 occupancy. (B) Heatmaps showing log2 ratio of H2Bub ChIP-seq densities were plotted based on increasing gene length. (C and D) Metagene plots of H2Bub ChIP-seq read densities in Paf1-KO cells with (+) or without (−) Dox treatment in different groups. Genes were grouped according to expression level (C; high [FPKM > 30] or low (0 < FPKM < 30) expression) or length (D; long [>20 kb], intermediate [10 kb < gene length < 20 kb], and short [<5 kb]), as indicated. (E) H2Bub ChIP-seq for individual short or long genes are shown. Zoomed-in shaded rectangular area denotes region with decreased H2Bub levels. (F) A metagene plot of normalized H2Bub ChIP-seq densities over regions 5 kb upstream to 100 kb downstream of the TSS (+Dox versus −Dox). (G) Scatterplots of log2 fold changes of normalized Ser5P occupancy versus log2 fold changes of normalized H2Bub in 2 regions (TSS to +20 kb and +20 kb to TES) in Paf1-KO cells.
Fig. 5. Paf1 loss dramatically hampers transcriptional elongation. (A) Heatmaps showing log₂ fold change (−Dox/+Dox) of normalized Proseq read densities for genes in both forward (n = 3,023) and reverse (n = 2,745) strands within 2-kb regions flanking the TSS before or after Paf1 depletion in Paf1-KO cell. Both sense and antisense directions for both strands are indicated. (B) Metagene analysis of Proseq data for both sense and antisense directions in regions within 2 kb of the TSS. (C) Analysis as in A, but plotted as a function of gene length in Paf1-KO cells expressing (+Dox) or lacking (−Dox) Paf1 expression. (D) Metagene plot of mean log₂ ratios shows that the increase in Proseq reads correlates with the accumulation of Ser5P, RNA-seq reads, and the reduction of H2Bub over an early ∼20- to 30-kb gene body window. Data in SI Appendix, Fig. S7 were replotted here for comparison. (E) Metagene plots of Proseq data at each time interval after DRB treatment (0, 5, 15, and 30 min) over the entire gene body plus 5-kb flanking regions upstream of TSS and downstream of TES. RPM, reads per million. (F) Proseq data are shown for two individual genes before (+Dox) and after (−Dox) Paf1 ablation at each time point after DRB treatment (0, 5, 15, and 30 min). Note that the "travel distance" of engaged Pol II after DRB treatment was affected by Paf1 ablation (+Dox versus −Dox). (G) Heatmaps show the log₂ fold change of normalized Proseq signal in DRB treatment time points (5 min, 15 min, and 30 min) compared with untreated control (0 min) in +Dox and −Dox conditions. Note that the red color indicates the "travel distance" of engaged Pol II after DRB treatment. (H) Elongation rates were calculated using a HMM method. Boxplots show the distribution of elongation rates in cells expressing (blue) or lacking (red) Paf1 at indicated time intervals before and after Paf1 removal. *P < 0.01 by Wilcoxon rank-sum test. Note the compressed distribution of elongation rates after Paf1 removal.
body when calculating read counts, without distinguishing whether transcripts are prematurely terminated) could underestimate the number of differentially expressed/regulated genes in SI Appendix, Fig. S7A. Moreover, we found that genes down-regulated after Paf1 depletion tended to be highly expressed (with higher Paf1 occupancy), whereas up-regulated genes tended to be weakly expressed (with lower Paf1 occupancy), suggesting that up-regulation could result from an indirect effect of Paf1 ablation (SI Appendix, Fig. S7G). Our previous work suggested that loss of Paf1 leads to defects in PAS usage, which resulted in production of aberrant, prematurely shortened transcripts in early exons and introns (7). Our current RNA-seq data (and Proseq data below) suggest that Pol II stalling over early gene bodies is likely to explain this increased frequency of premature processing.

Loss of Paf1C Results in Significant Reductions in Elongation Rate.

Given the observed changes in nucleosome density, accumulation of Ser5 phosphorylated Pol II, H2Bub reductions, and increased prematurely terminated transcripts from early gene body regions after Paf1 depletion, we investigated whether the loss of Paf1 could impinge on Pol II elongation rates. A prior study in which run-on transcription assays were coupled to genome-wide sequencing of nascent RNA suggested that, in some cell types, Paf1 could act as a negative regulator of elongation through the enforcement of pausing and that removal of Paf1 could trigger release of paused Pol II into gene bodies (10). However, one alternative explanation for these data could not be ruled out, namely, that Paf1 could function like a positive elongation factor such as Spt5. Notably, knockdown of Spt5 resulted in the increased density of Pol II across gene bodies, prompting the conclusion that loss of this factor promotes release of Pol II from promoters (42, 43). Computational modeling and further experimentation, on the other hand, suggested that the observed increases in Pol II density could stem from reduced processivity or elongation rates in early gene body regions after Spt5 removal (35, 37, 43).

To distinguish the effects on elongation in gene bodies versus promoter clearance, we performed genome-wide precision nuclear run-on and sequencing (Proseq) to analyze nascent RNA production, as well as active Pol II density, location, directionalities, and rates in Paf1-KO cells (44, 45). We examined our KO cells in the presence or absence of Dox and performed a time course in which we treated cells with 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole (DRB) to block CDK9 activity for 5, 15, and 30 min, enabling us to observe Pol II escape from a promoter-proximal pause and calculate elongation rates over the duration of treatment. We showed that this method was robust, and data from replicates were highly correlated (SI Appendix, Fig. S8A). Heatmap and metagene analyses show that the nascent RNA signal was significantly reduced at the TSS-proximal region in both directions, followed by an increased level of nascent RNA downstream in the sense direction, but not in the antisense direction (Fig. 5A and B). The decreased promoter-proximal nascent RNA peak suggests a reduction in initiation (see Discussion). When we plotted the heatmaps based on gene length, we found that the increased Pol II density was restricted to early gene body regions (Fig. 5C). Remarkably, there was a near-precise overlap between these increased nascent reads and the accumulation of Ser5P, increases in prematurely terminated transcripts, and the reduction in H2Bub (Fig. 5D). Moreover, scatterplot analysis shows that the increased Proseq signal correlated with a decrease in H2Bub and accumulation of Ser5P Pol II over the first 20 kb, but not in the region from 20 kb downstream of the TSS to TES (SI Appendix, Fig. S8 B and C). Over the course of DRB treatment, we observed that the Pol II elongation rate was significantly reduced in Paf1-depleted cells, as shown in both metagene and single-gene analyses (Fig. 5 E and F). When we plotted Proseq density heatmaps showing log2 ratios of later time points (5 min, 15 min, and 30 min after DRB treatment) versus untreated cells (0 min) in the presence or absence of Paf1 over 5,846 nonoverlapping expressed genes, we found that the elongation rates were more “homogenized” or compressed after loss of Paf1, irrespective of gene length (Fig. 5G) (note the width of the red “band” in Fig. 5G after Dox removal). Next, we used these Proseq density maps to generate line plots based on the log2 ratios, which allowed us to approximate the mean “travel distance” over various time intervals, and we found the mean travel distance at the beginning of DRB treatment (0 to 5 min) was ~12 kb in the +Dox condition, whereas the travel distance was significantly reduced after Paf1 depletion (~5 kb) (0 to 5 min; SI Appendix, Fig. S8D). Notably, Pol II took 15 min or 30 min to travel through the first ~12 kb or ~28 kb, respectively, in Paf1-depleted cells, whereas Pol II required 5 min or 15 min, respectively, to travel the same distance in Paf1-replicate cells (SI Appendix, Fig. S8D).

Next, we employed a hidden Markov model (HMM) to identify the position of the “wave front” of engaged Pol II on a subset of genes longer than 70 kb and to infer Pol II elongation rates during the DRB time course (Materials and Methods). We calculated average elongation rates of 1.80 kb/min (5- to 15-min interval) and 1.72 kb/min (15- to 30-min interval) in the presence of Paf1 (Fig. 5H), which are comparable to average elongation rates of ~2 kb/min deduced using other mammalian cell lines with related computational methods (2, 46, 47). In contrast, we found that Paf1 removal led to substantially reduced elongation rates, with average elongation rates of 1.20 kb/min (5- to 15-min interval) and 1.26 kb/min (15- to 30-min interval) in Paf1-KO cells lacking Paf1, and the impact of Paf1 loss was evident at both early (5 to 15 min) and late (15 to 30 min) time intervals (Fig. 5H; P < 0.01).

Since Pol II elongation rates were compressed into a very narrow range in the absence of Paf1, compared with Paf1-replicate cells at all time intervals (Fig. 5 G and H), we conclude that Paf1 plays a rate-limiting role in Pol II elongation through early gene bodies (Fig. 6). Our studies also unify prior findings and suggest that the removal of Paf1 triggers significant genome-wide reductions in Pol II elongation rates, reinforcing the role of Paf1C as an essential elongation factor that functions beyond the pause-release step.

Discussion

Experiments in cancer cells have suggested that loss of Paf1 results in pause release (10), a finding at variance with the studies presented here and with those in yeast, which...
support a positive role for Paf1 in transcriptional elongation. In contrast, we found that silencing Paf1 results in Pol II accumulation owing to a reduced elongation rate. It is possible that differences in cell types could explain this discrepancy (10). If true, this would suggest that Paf1C plays opposite roles in nontransformed and transformed cells. However, we favor an alternative, parsimonious explanation that comports with mathematical modeling of other elongation factors (43), namely, that Paf1C is a positive elongation factor that promotes efficient elongation, allowing Pol II to attain optimal speed and processivity in the first 20–30 kb of gene bodies (Fig. 6). The altered distribution of Pol II observed here is distinct from previously studied promoter-proximal pausing, which occurs ~25 to 50 bp from the TSS (1). Indeed, upon Paf1 depletion, Pol II accumulation occurred over a much greater distance from the TSS, ~20 to 30 kb downstream of TSS. This suggests that the increased Pol II accumulation around the promoter-proximal region upon loss of Paf1 could also result from the reduced elongation rate provoked by loss of Paf1. Since the aberrant Pol II accumulation expands to a region well beyond the TSS-proximal Pol II pause site, we propose that Paf1 regulates Pol II distribution beyond the promoter-proximal pause point. Our findings therefore suggest a revised model for Paf1 function that explains previously divergent conclusions (Fig. 6) (6, 10).

In addition, H2Bub levels have been shown to strongly correlate with Pol II elongation rates in multiple cell lines (20). Although genic elongation rates appear highly variable, Pol II was shown to systematically accelerate as it progressed through early gene bodies in human cells (2, 46). Our studies indicate that Paf1-mediated H2B ubiquitilation could play a particularly important role in regulating early elongation, where diminution of H2Bub over Paf1-depleted genes strongly correlates with a reduction in Pol II elongation rates (Fig. 5D). This finding stands in stark contrast to another histone modification, H3K36me3, which is aberrantly shifted toward 5′ regions of genes with slow Pol II (48). Interestingly, we were able to reproduce this finding using our own data (SI Appendix, Fig. S8E), and these findings suggest that the observed elevation in H3K36me3 triggered by secondly H2Bub over Paf1-depleted genes strongly correlates with a reduction in Pol II elongation rates (Fig. S5D). This finding stands in stark contrast to another histone modification, H3K36me3, which is aberrantly shifted toward 5′ regions of genes with slow Pol II (48). Interestingly, we were able to reproduce this finding using our own data (SI Appendix, Fig. S8E), and these findings suggest that the observed elevation in H3K36me3 triggered by decreased Paf1 Pol II dwell time is not restricted to use of slow Pol II mutants described previously (48). Notably, we also found that in the absence of Paf1, H2Bub was most dramatically compromised over the first ~20 to 30 kb of gene bodies, whereas distal gene body regions were less significantly impacted. This result suggests mechanistic differences in the deposition and/or maintenance of this histone modification as a function of gene length, and future studies will be required to identify the molecular basis of this observation. Intriguingly, we note that mammalian Spt5 plays a role over a critical window ~15 to 20 kb downstream of the TSS, whereas this window is condensed to ~500 bp in yeast, which has considerably shorter genes (35, 37). Future studies will be required to determine whether Spt5 and Paf1C are mechanistically linked within this window, although our data clearly show that recruitment of these factors is not obligatorily connected (SI Appendix, Fig. S5).

It has been shown that elongation is normally slower in early gene body regions compared with downstream genic regions in normal conditions, with Pol II gradually accelerating through the gene body until it reaches maximum elongation speed (2, 46). We propose that this may explain why Pol II tends to slow down more obviously in this region after loss of Paf1. Further, slow polymerase may also lead to the accumulation of paused Pol II around promoter-proximal regions and thereby inhibit transcriptional initiation, consistent with our Proseq data (Fig. 5A and B) and recent reports (49, 50).

Another interesting finding from our studies is that ablating of Paf1 compressed the elongation rates of genes globally to a considerably narrower range within the first ~28 kb (Fig. 5G and SI Appendix, Fig. S8D). It is known that elongation rates vary widely across the transcriptome (46). Previous studies in mammalian cells indicated that elongation rates could vary by up to 5-fold, ranging from 0.5 to 2.4 kb/min (46). In addition, these studies indicated significant variation within each group of elongation rates, on the order of ~0.4 to 0.8 kb/min. Thus, it is interesting that removal of Paf1 not only reduces overall Pol II elongation speeds but also results in a more homogeneous elongation rate. Our data suggest that Paf1C could be a fine-tuning, “rheostat-like” factor whose recruitment helps dictate the observed variance in elongation speeds by accelerating Pol II progression in a yet-to-be-discovered manner. It will be interesting to determine the factors other than Paf1C that contribute to elongation rate variation.

Furthermore, we observed a striking increase in nucleosome occupancy after Paf1 removal, concomitant with increased TSS-proximal Pol II pausing and reduced initiation and elongation rates. It is well documented that the first few downstream nucleosomes are a major barrier to Pol II progression (15–18). The increased nucleosome density observed after loss of Paf1 could thus account for the accumulation of TSS-proximal unphosphorylated Pol II and decreased initiation rates observed in our Proseq experiments. However, others have observed distinct profiles: RNA Pol II pausing at highly regulated genes was shown to be characterized by reduced nucleosome occupancy within the early transcribed region and nucleosomal occlusion of their promoters, while housekeeping genes exhibited the opposite pattern (51). Further studies are needed to elucidate the interplay between Pol II pausing and nucleosome occupancy around promoters and regions downstream of the TSS in mammalian cells.

Importantly, our findings lead to several major conclusions and a revised model for Paf1C function: 1) Reminiscent of findings with Spt5 (35, 37), there is a transcriptional window within early gene body regions essential for control of Pol II elongation rates; 2) Paf1C controls the rate of Pol II elongation and plays an instrumental role in elongation throughout this window; and 3) Paf1C could play a more persistent role within this region as a polymerase “accelerator” by functioning after pause release (Fig. 6). Indeed, 2 of our findings strongly suggest a role for Paf1C beyond promoter-proximal pause release (6). First, pause release occurs as a byproduct of CDK9 phosphorylation of Ser2, but we did not see a global reduction in phosphorylated Ser2 of Pol II CTD after Paf1 reduction. On the contrary, we observed an increase in this form of modified Pol II (SI Appendix, Fig. S3C). Second, we observed that DRB treatment was able to prevent pause release in Proseq experiments, both in sense and antisense directions, even after removal of Paf1 (SI Appendix, Fig. S8F). This suggests that CDK9-mediated pause release may still be enforced in Paf1-depleted cells. Thus, we propose that Paf1C function is crucial for Pol II elongation over a specialized region within ~20 to 30 kb downstream of the TSS (Fig. 6). Future studies will be required to reveal the entire complement of factors required to promote elongation through this window.

Finally, we propose that drastic reductions in Pol II elongation rates and accumulation of Pol II over the first ~20 to 30 kb region could explain the usage of alternative polyA sites and transcript shortening at early introns that we observed previously (7). This phenomenon, whereby slow Pol II promotes skipping of polyA site usage, is well documented in fruits flies and human cells (52, 53). Our findings suggest that an imbalance in Paf1C activity could trigger the production of immature nascent transcripts.

**Materials and Methods**

All siRNA sequences and antibodies used in this study are listed in SI Appendix, Tables S1 and S2, respectively. See SI Appendix, Materials and Methods.
1. K. Adelman, J. T. Lis, Promoter-proximal pausing of RNA polymerase II: Emerging roles in metaozoa. Nat. Rev. Genet. 13, 720–731 (2012).
2. C. G. Danko et al., Signaling pathways differentially affect RNA polymerase II initiation, pausing, and elongation rate in cells. Mol. Cell 56, 212–222 (2015).
3. J. A. Jaehning, The Paf1 complex: Platform or player in RNA polymerase II transcription? Biochim. Biophys. Acta 1799, 379–388 (2010).
4. S. B. Van Ous, C. E. Cucinotta, K. M. Arndt, Emerging insights into the roles of the Paf1 complex in gene regulation. Trends Biochim. Sci. 42, 788–796 (2017).
5. A. Mayer et al., Uniform transitions of the general RNA polymerase II transcription complex. Nat. Struct. Mol. Biol. 27, 1272–1278 (2010).
6. M. Yu et al., RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science 350, 1383–1386 (2015).
7. Y. Yang et al., PAF complex plays novel subunit-specific roles in alternative cleavage and polyadenylation. PLoS Genet. 12, e1005794 (2016).
8. S. M. Vos, L. Farmung, H. Urlaub, C. P. Ramer, Structure of paused transcription complex Pol II-DSSF-NELF. Nature 560, 601–606 (2018).
9. S. M. Vos et al., Structure of activated transcription complex Pol II-DSSF-PAF-SPT6. Nature 560, 607–612 (2018).
10. F. X. Chen et al., PAF1, a molecular regulator of promoter-proximal pausing by RNA polymerase II. Cell 162, 1003–1015 (2015).
11. F. X. Chen et al., PAF1 regulation of promoter-proximal pause release via enhancer activation. Science 357, 1294–1298 (2017).
12. L. Wu, L. Li, B. Zhou, Z. Qin, Y. Dou, H2B ubiquitylation promotes RNA Pol II processivity via PAF1 and PTEFb. Nat. Cell Biol. 54, 920–931 (2014).
13. M. Patturajan et al., Growth-related changes in phosphorylation of yeast RNA polymerase II. J. Biol. Chem. 273, 4689–4694 (1998).
14. H. Fischl, F. S. Howe, A. Furger, J. MeUer, Pol2 has distinct roles in transcription elongation and differential transcript fate. Mol. Cell 65, 685–698.e6 (2017).
15. V. A. Bondarenko et al., Nucleosomes can form a polar barrier to transcription elongation by RNA polymerase II. Mol. Cell 24, 469–479 (2006).
16. L. S. Churchman, J. S. Weissman, Nascent transcript sequencing visualizes transcription at nucleotide resolution. Nature 469, 368–373 (2011).
17. C. M. Weber, S. Ramachandran, S. Henikoff, Nucleosomes are context-specific, H3A.Z-modulated barriers to RNA polymerases. Mol. Cell 53, 819–830 (2014).
18. T. Kuji et al., Structural basis of the nucleosome transition during RNA polymerase II passage. Science 362, 595–598 (2018).
19. R. Pavi et al., Histone H2B monoubiquitination functions cooperatively with FACT to regulate elongation by RNA polymerase II. Cell 125, 703–717 (2006).
20. G. Fuchs, D. HofferU, Y. Voitchek, G. Ast, M. Oren, Cotranscriptional histone H2B monoubiquitination is tightly coupled with RNA polymerase II elongation rate. Genes Dev. 28, 1572–1583 (2014).
21. A. K. BoeU, A. Saunders, J. Werner, J. T. Lis, Transcription factor and polymerase recruitment, modification, and movement on dHSp70 in vivo in the minutes following heat shock. Mol. Cell. Biol. 23, 7628–7637 (2003).
22. O. Rozenblatt-Rosen et al., The tumor suppressor Cdc73 functionally associates with CP190 and Ctf7 in mRNAP processing factors. Proc. Natl. Acad. Sci. U.S.A. 106, 755–760 (2009).
23. D. Balaita et al., Integrator, a multiprotein mediator of small nuclear RNA processing, associates with the C-terminal repeat of RNA polymerase II. Cell 123, 265–276 (2005).
24. D. Balaita, E. J. Wagner, Integrator: Surprisingly diverse functions in gene expression. Trends Biochim. Sci. 40, 257–264 (2015).
25. B. Stadlmayr et al., Integrator complex regulates NELF-mediated RNA polymerase II pausing and processivity at coding genes. Nat. Commun. 5, 5531 (2014).
26. F. Lai, L. Arndt, A. Zhang, R. Shiekhattar, Integrator mediates the biogenesis of enhancer RNAs. Nature 525, 399–403 (2015).
27. P. Preker et al., RNA exosome depletion reveals transcription upstream of active human promoters. Science 322, 1851–1854 (2008).
28. C. Klicht, S. Wissmann, L. Vasiljeva, The regulation and functions of the nuclear RNA exosome complex. Nat. Rev. Mol. Cell Biol. 17, 227–239 (2016).

ACKNOWLEDGMENTS. We thank the New York University Genome Technology and Proteomics cores, particularly S. Nayak, T. Uebelheide, P. Meyn, and A. Heguy. We thank M. Hoque (Rutgers New Jersey Medical School) for assistance with library preparation. We thank Y. Yang for Hn2Bip-Seq data. We thank D. Reinberg and G. LeRoy for the generous gift of antibodies. I.S. and E.N. were supported in part by NIH ROI GM062689, the Blavatnik Family Foundation, and by the Howard Hughes Medical Institute. B.D.D. was supported by NIH Grant R01GM122395.